Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

oche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin, Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans and timing for the initiation of the TIME-1 trial and TIME-2 as a potential registration trial, and the FDA's later review of the results of the TIME-1 clinical trial. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies and ongoing trials may not demonstrate safety and efficacy sufficient to initiate additional clinical trials, continue clinical development on the timing currently anticipated or at all, obtain the requisite regulatory approvals or result in a marketable product; risks related to regulatory requirements and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward- looking statements.

'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... 04, 2015 , ... The American Academy of Thermology ... internationally peer-reviewed Guidelines were prepared by members of the AAT as a guide ... patients with dental-oral and systemic health-related complaints. , Thermography is a non-invasive ...
(Date:8/3/2015)... ... 03, 2015 , ... Representatives with Health Food Grocers today announced ... ‘Ask a Nutritionist’ feature on our website is a free service to our community ... and spokeswoman for Health Food Grocers. , Health Food Grocers’ website offers a variety ...
(Date:8/3/2015)... ... 03, 2015 , ... According to an opinion piece published July 28 by the ... one pound of weight loss may not be accurate. While this system may work for ... of fat varies – based both on the individual and at what point that person ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and the largest online retailer of nutritional supplements, has officially opened the ... for 11 awards in the following categories:, ,     Brand ...
Breaking Medicine News(10 mins):Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3
... , , WASHINGTON, July 30 ... employer-based coverage if Congress passes a House health reform bill, according ... Act of 2009 released this week by ... Heritage commissioned The Lewin Group , a highly ...
... ... ... shows that men and women who are divorced or widowed have an increased chance of ... , ,The study, which appears in the September issue of Journal of Health and Social Behavior, ...
... , WASHINGTON July ... and Commerce Committee to prohibit cost-sharing to Medicaid patients for ... President Robert J. Gould praised an amendment offered by Rep. ... being crafted by the Committee. Her amendment would eliminate cost-sharing ...
... a big role in immune response, study finds, , THURSDAY, ... down there with the appendix, the spleen isn,t exactly known ... fine without it. , But new research suggests the spleen ... thought. , In mice, scientists found, the spleen serves as ...
... , - New NMA President to ... , LAS VEGAS, July 30 Delivering her inaugural ... Willarda V. Edwards, MD, MBA, shared her plans to focus on ... is the nation,s premier organization for African American physicians. , ...
... , SANTA CLARA, Calif., July 30 ... and green products for the home and body, today announced the ... of the proceeds from the sale of the box to cancer ... is a truly helpful gift when a friend or loved one ...
Cached Medicine News:Health News:Millions of Virginians Could Lose Private Insurance, Study Shows 2Health News:Study Shows Divorced, Widowed Adults Have Increased Health Risks 2Health News:Study Shows Divorced, Widowed Adults Have Increased Health Risks 3Health News:Eliminate Cost-Sharing for Medicaid Preventive Services, Partnership Urges House Committee 2Health News:Spleen May Help Heart Recover From Disease 2Health News:National Medical Association Installs 110th President at Las Vegas Convention 2Health News:Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment 2
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
The revision knee system for severe joint deterioration with insufficient ligament support....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
The GENESIS II* Total Knee System will define the state of knee implants....
Medicine Products: